is "so good" that it's going to $76 from a recent $66.83, Jim Cramer said Friday on
"Stop Trading!" segment.
Cramer said Yum's KFC is "the dominant food in China," which is why Friday's Deutsche Bank upgrade makes sense. Cramer notes that the stock is up 20% in recent months off this spring's rodent filming at a Taco Bell in New York's Greenwich Village.
Cramer also likes
heading into next week's biotech conferences, saying that Nastech is playing a secular trend with its obesity drug and that Acadia has a treatment for Parkinson's disease and schizophrenia that doctors are excited about.
is a "great story to trade" off next Wednesday's expected Food and Drug Administration decision on its Acomplia weight-loss drug. Cramer said the FDA "is under great pressure" on obesity.
At the time of publication, Cramer had no position in stocks mentioned.
Jim Cramer is a director and co-founder of TheStreet.com. He contributes daily market commentary for TheStreet.com's sites and serves as an adviser to the company's CEO. Outside contributing columnists for TheStreet.com and RealMoney.com, including Cramer, may, from time to time, write about stocks in which they have a position. In such cases, appropriate disclosure is made. To see his personal portfolio and find out what trades Cramer will make before he makes them, sign up for
Action Alerts PLUS. Watch Cramer on "Mad Money" weeknights on CNBC. Click
here to order Cramer's latest book, "Mad Money: Watch TV, Get Rich," click
here to order his book, "Real Money: Sane Investing in an Insane World," click
here to get his second book, "You Got Screwed!" and click
here to order Cramer's autobiography, "Confessions of a Street Addict." While he cannot provide personalized investment advice or recommendations, he invites you to send comments on his column by
TheStreet.com has a revenue-sharing relationship with Traders' Library under which it receives a portion of the revenue from Traders' Library purchases by customers directed there from TheStreet.com.